drugset
drugset / Trial / NCT02429973

Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma

NCT02429973 ↗

Phase 2 Completed 33 enrolled Broto, Javier Martín, M.D.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Multicenter and prospective phase II trial with gemcitabine and rapamycin in second line of metastatic osteosarcoma. The study includes 6 cycles of the combination gemcitabine+rapamycin in metastatic or unresectable osteosarcoma patients.

Timeline

Start
2012-07
Primary completion
2014-12
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 800 mg/m2 —
Subject Rapamycin Small molecule 5 mg —

Indications

osteosarcoma